Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CC transcript
Quarterly results
Appointed director
ACURA PHARMACEUTICALS, INC (ACUR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2018 GN Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results
06/29/2018 GN Acura Pharmaceuticals Announces First Quarter 2018 Financial Results
06/07/2018 GN Acura Pharmaceuticals Announces Fourth Quarter 2017 and Full Year 2017 Financial Results
01/08/2018 GN Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
11/13/2017 GN Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results
09/11/2017 GN Acura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
08/31/2017 GN Acura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
08/14/2017 GN Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results
07/24/2017 GN Acura Pharmaceuticals Raises $4.0 Million in a Private Placement
05/18/2017 GN Acura Pharmaceutical Initiates Second Clinical Study on LTX-04
05/12/2017 GN Acura Pharmaceuticals Announces First Quarter 2017 Financial Results
03/31/2017 GN Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
03/17/2017 GN Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products
02/15/2017 GN Acura Pharmaceuticals Common Stock To Trade On The OTCQB Market
07/11/2011 GN Robert Jones Appointed President ' CEO and to the Board of Directors of Acura Pharmaceuticals, Inc.
07/08/2011 GN Acura Pharmaceuticals, Inc. Announces the Retirement of William A. Sumner From Board of Directors
07/01/2011 GN Acura Pharmaceuticals Receives $20 Million Milestone Payment
06/06/2011 GN Acura Pharmaceuticals, Inc. Announces Notice of Allowance for Third Aversion(R) Technology Patent
05/02/2011 GN Acura Pharmaceuticals, Inc. Announces Appointment of Robert Jones as Interim President and CEO
04/29/2011 GN Acura Pharmaceuticals, Inc. Announces the Passing of Andrew Reddick, President ' CEO
04/28/2011 GN Acura Pharmaceuticals Reports First Quarter 2011 Financial Results and Product Development Update
04/25/2011 GN Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President ' CEO, to Take Medical Leave
03/01/2011 GN Acura Pharmaceuticals Reports Year-End and Fourth Quarter 2010 Financial Results and Product Development Update
02/14/2011 GN ACUROX(R) Tablets New Drug Application Accepted for Filing With a Priority Review Classification
11/02/2010 GN Acura Pharmaceuticals Reports 3rd Qtr 2010 Financial Results and Product Development Update
09/13/2010 GN Acura Pharmaceuticals Named in Purported Class Action Securities Litigation
07/29/2010 GN Acura Pharmaceuticals Reports Second Quarter 2010 Financial Results
04/22/2010 GN NASDAQ Halts Trading in Acura Pharmaceuticals Stock Pending Outcome of FDA Advisory Committee Meeting
04/22/2010 GN NASDAQ Halts Trading in Acura Pharmaceuticals Stock Pending Outcome of FDA Advisory Committee Meeting
04/21/2010 GN Acura Pharmaceuticals Reports First Quarter 2010 Financial Results
04/21/2010 GN Acura Pharmaceuticals Reports First Quarter 2010 Financial Results
04/20/2010 GN FDA Posts Briefing Documents for April 22nd Joint Advisory Committee Meeting on Acurox(R)
04/20/2010 GN FDA Posts Briefing Documents for April 22nd Joint Advisory Committee Meeting on Acurox(R)
03/17/2010 GN FDA Schedules Joint Advisory Committee Meeting for Acurox(R)
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy